Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing

Journal of Clinical Oncology

Volumn 25, Issue 3, 2007, Pages 285-291

  Tercyak, Kenneth P ^a   Peshkin, Beth N ^a   Brogan, Barbara M ^a   DeMarco, Tiffani ^a   Pennanen, Marie F ^a   Willey, Shawna C ^a   Magnant, Colette M ^a   Rogers, Sarah ^a   Isaacs, Claudine ^a   Schwartz, Marc D ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; FEMALE; GENETIC COUNSELING; GENETICS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; AGED; BREAST TUMOR; GENETIC PREDISPOSITION; MENTAL STRESS; MIDDLE AGED; PSYCHOLOGICAL ASPECT; SECOND CANCER; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; QUALITY OF LIFE; STRESS, PSYCHOLOGICAL;

EID: 33846908291     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.3890     Document Type: Article

References (40)

1. Society of Surgical Oncology: Position statement on prophylactic mastectomy. http://www.surgonc.org/default.aspx?id=47
2. Metcalfe K, Lynch HT, Ghadirian P, et al: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335, 2004
3. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271, 1995
4. Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316, 1999
5. Robson M, Svahn T, McCormick B, et al: Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 103:44-51, 2005
6. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology-v. 1.2006. Genetic/familial high-risk assessment: Breast and ovarian. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf
7. Peshkin BN, Isaacs C: Evaluation and management of women with BRCA1/2 mutations. Oncology (Williston Park) 19:1451-1459, 2005
8. Herrinton LJ, Barlow WE, Yu O, et al: Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project. J Clin Oncol 23:4275-4286, 2005
9. McDonnell SK, Schaid DJ, Myers JL, et al: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938-3943, 2001
10. van Sprundel TC, Schmidt MK, Rookus MA, et al: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93:287-292, 2005
11. Schwartz MD, Lerman C, Brogan B, et al: Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 14:1003-1007, 2005
12. Weitzel JN, McCaffrey SM, Nedelcu R, et al: Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138:1323-1328, 2003
13. Evans DG, Lalloo F, Hopwood P, et al: Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol 31:1112-1118, 2005
14. Stolier AJ, Corsetti RL: Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation. Am Surg 71:1031-1033, 2005
15. Schwartz MD, Lerman C, Brogan B, et al: Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22:1823-1829, 2004
16. Helzlsouer KJ: Contralateral prophylactic mastectomy: Quantifying benefits and weighing the harms. J Clin Oncol 23:4251-4253, 2005
17. Schwartz MD: Contralateral prophylactic mastectomy: Efficacy, satisfaction, and regret. J Clin Oncol 23:7777-7779, 2005
18. Frost MH, Slezak JM, Tran NV, et al: Satisfaction after contralateral prophylactic mastectomy: The significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 23:7849-7856, 2005
19. Geiger AM, West CN, Nekhlyudov L, et al: Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 24:1350-1356, 2006
20. Frost MH, Schaid DJ, Sellers TA, et al: Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319-324, 2000
21. American Society of Clinical Oncology: ASCO policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406, 2003
22. Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415, 1997
23. Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425, 1998
24. Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158, 1998
25. Robson M, Dabney MK, Rosenthal G, et al: Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1:47-51, 1997
26. Schwartz MD, Hughes C, Roth J, et al: Spiritual faith and genetic testing decisions among highrisk breast cancer probands. Cancer Epidemiol Biomarkers Prev 9:381-385, 2000
27. Schwartz MD, Peshkin BN, Hughes C, et al: Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 20:514-520, 2002
28. Schwartz MD, Kaufman E, Peshkin BN, et al: Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 21:4034-4041, 2003
29. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
30. Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974-986, 1997
31. Horowitz M, Wilner N, Alvarez W: Impact of Event Scale: A measure of subjective stress. Psychosom Med 41:209-218, 1979
32. Cella D, Hughes C, Peterman A, et al: A brief assessment of concerns associated with genetic testing for cancer: The Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol 21:564-572, 2002
33. Nekhlyudov L, Bower M, Herrinton LJ, et al: Women's decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr 35:55-60, 2005
34. Ganz PA, Rowland JH, Meyerowitz BE, et al: Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 152:396-411, 1998
35. Shimozuma K, Ganz PA, Petersen L, et al: Quality of life in the first year after breast cancer surgery: Rehabilitation needs and patterns of recovery. Breast Cancer Res Treat 56:45-57, 1999
36. Coyne JC, Kruus L, Racioppo M, et al: What do ratings of cancer-specific distress mean among women at high risk of breast and ovarian cancer? Am J Med Genet A 116:222-228, 2003
37. Daly MB: Tailoring breast cancer treatment to genetic status: The challenges ahead. J Clin Oncol 22:1776-1777, 2004
38. Palomares MR, Paz B, Weitzel JN: Genetic cancer risk assessment in the newly diagnosed breast cancer patient is useful and possible in practice. J Clin Oncol 23:3165-3166, 2005
39. Ardern-Jones A, Kenen R, Eeles R: Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care (Engl) 14:272-281, 2005
40. Stolier AJ, Fuhrman GM, Mauterer L, et al: Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation. Breast J 10:475-480, 2004